COAG Stock — Hemab Therapeutics Holdings, Inc.: Metrics

Market overview

2 metrics

Share price

$30.59

Market cap

$1.52B

Price action

20 metrics

Price change (1W)

-10.4%

Price change (30D)

-30.2%

Price change (3M)

+0.4%

Price change (6M)

—

Price change (YTD)

—

Price change (1Y)

—

Trailing year

Price change (5Y)

—

52-week high

—

52-week low

—

Change from 52-week high

—

Change from 52-week low

—

Annualized volatility

89.5%

Annualized volatility (3M)

72.5%

Beta

1.5

RSI (14D)

23.2

Price vs SMA 50

-30.1%

Price vs SMA 200

—

Avg volume (3M)

454,320

Relative volume

0.8

Average dollar volume

$19.53M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

46.71M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

3.3

reciprocal yield 30.0%

FCF yield

—

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

—

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-08-11

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

—

Net income (TTM)

—

Trailing 12 months

Diluted EPS (TTM)

—

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

—

Growth

11 metrics

Revenue growth YoY

—

Year over year

Net income growth YoY

—

Revenue (TTM)

—

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+3,083.0%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

—

Return on assets

—

Debt / equity

—

Current ratio

35.8

EBITDA (TTM)

—

Free cash flow (TTM)

—

Quick ratio

35.8

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$457.46M

Latest balance sheet

Cash & equivalents

$237.37M

Total assets

$467.78M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

—

Capital expenditures (TTM)

—

R&D (TTM)

—

SG&A (TTM)

—

Stock compensation (TTM)

—

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

56

13F filer change QoQ

+56

Institutional ownership

77.6%

Short interest

3 metrics

Short interest

5.7%

Latest settlement · 7.5 days to cover

Days to cover

7.5d

Short-squeeze score

71 / 100

Insider activity

2 metrics

Net insider buying (90D)

—

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

COAG · Hemab Therapeutics Holdings, Inc. · Metrics

COAG metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search